Deuterium MRSI of tumor cell death in vivo following oral delivery of 2H‐labeled fumarate
Open Access
- 11 July 2022
- journal article
- research article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 88 (5) , 2014-2020
Abstract
Purpose: There is an unmet clinical need for direct and sensitive methods to detect cell death in vivo, especially with regard to monitoring tumor treatment response. We have shown previously that tumor cell death can be detected in vivo from 2H MRS and MRSI measurements of increased [2,3‐2H2]malate production following intravenous injection of [2,3‐2H2]fumarate. We show here that cell death can be detected with similar sensitivity following oral administration of the 2H‐labeled fumarate.Methods: Mice with subcutaneously implanted EL4 tumors were fasted for 1 h before administration (200 μl) of [2,3‐2H2]fumarate (2 g/kg bodyweight) via oral gavage without anesthesia. The animals were then anesthetized, and after 30 min, tumor conversion of [2,3‐2H2]fumarate to [2,3‐2H2]malate was assessed from a series of 13 2H spectra acquired over a period of 65 min. The 2H spectra and 2H spectroscopic images were acquired using a surface coil before and at 48 h after treatment with a chemotherapeutic drug (etoposide, 67 mg/kg).Results: The malate/fumarate signal ratio increased from 0.022 ± 0.03 before drug treatment to 0.12 ± 0.04 following treatment (p = 0.023, n = 4). Labeled malate was undetectable in spectroscopic images acquired before treatment and increased in the tumor area following treatment. The increase in the malate/fumarate signal ratio was similar to that observed previously following intravenous administration of labeled fumarate.Conclusion: Orally administered [2,3‐2H2]fumarate can be used to detect tumor cell death noninvasively following treatment with a sensitivity that is similar to that obtained with intravenous administration.Keywords
Funding Information
- Cancer Research UK (C197/A17242, C197/A16465, C9685/A25177)
This publication has 20 references indexed in Scilit:
- Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysisTherapeutic Advances in Neurological Disorders, 2014
- Subcutaneous Administration of Monoclonal Antibodies in OncologyGeburtshilfe und Frauenheilkunde, 2014
- Monitoring Chemotherapeutic Response by Hyperpolarized 13C-Fumarate MRS and Diffusion MRICancer Research, 2014
- Imaging Cell DeathJournal of Nuclear Medicine, 2014
- Magnetic resonance imaging with hyperpolarized [1,4- 13 C 2 ]fumarate allows detection of early renal acute tubular necrosisProceedings of the National Academy of Sciences, 2012
- Hyperpolarized 13C Spectroscopy Detects Early Changes in Tumor Vasculature and Metabolism after VEGF NeutralizationCancer Research, 2012
- Detection of Tumor Response to a Vascular Disrupting Agent by Hyperpolarized 13C Magnetic Resonance SpectroscopyMolecular Cancer Therapeutics, 2010
- Imaging tumour cell metabolism using hyperpolarized 13C magnetic resonance spectroscopyBiochemical Society Transactions, 2010
- Production of hyperpolarized [1,4- 13 C 2 ]malate from [1,4- 13 C 2 ]fumarate is a marker of cell necrosis and treatment response in tumorsProceedings of the National Academy of Sciences, 2009
- Improved Method for Accurate and Efficient Quantification of MRS Data with Use of Prior KnowledgeJournal of Magnetic Resonance, 1997